Abstract
Abstract only
- Title
- The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
- Creators
- Bradley J. Monk - Creighton UniversityRachel N. Grisham - Memorial Sloan Kettering Cancer CenterChristian Marth - Arbeitsgemeinschaft Gynäkologische Onkologie Austria (AGO-Austria), Innsbruck, AustriaSusana N. Banerjee - Royal Marsden NHS Foundation TrustFelix Hilpert - Arbeitsgemeinschaft Gynäkologische Onkologie StudiengruppeRobert L. Coleman - The University of Texas MD Anderson Cancer CenterEric Pujade-Lauraine - Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), Paris, FranceSandro Pignata - Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Naples, ItalyMansoor Raza Mirza - Nordic Society of Gynecologic OncologyAmit M. Oza - Princess Margaret Cancer CentreJosep M. del Campo - Spanish Ovarian Cancer Research GroupMartin Klaus Oehler - Royal Adelaide HospitalAdam James - Array BioPharmaJanna Christy-Bittel - Array BioPharmaEmma Barrett - Array BioPharmaAdam P. Boyd - Array BioPharmaIgnace Vergote - Belgian Gynaecological Oncology Group (BGOG), Leuven, Belgium
- Publication Details
- Journal of clinical oncology, Vol.32(15_suppl), pp.TPS5618-TPS5618
- Identifiers
- 991005968782402656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article